0000899866-21-000070.txt : 20210723
0000899866-21-000070.hdr.sgml : 20210723
20210723164413
ACCESSION NUMBER: 0000899866-21-000070
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210721
FILED AS OF DATE: 20210723
DATE AS OF CHANGE: 20210723
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brennan David R
CENTRAL INDEX KEY: 0001609305
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27756
FILM NUMBER: 211111389
MAIL ADDRESS:
STREET 1: C/O INSMED INCORPORATED
STREET 2: 10 FINDERNE AVENUE
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000899866
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133648318
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 121 SEAPORT BOULEVARD
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 4752302596
MAIL ADDRESS:
STREET 1: 121 SEAPORT BOULEVARD
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960111
4
1
wf-form4_162707303457502.xml
FORM 4
X0306
4
2021-07-21
1
0000899866
ALEXION PHARMACEUTICALS, INC.
ALXN
0001609305
Brennan David R
C/O ALEXION PHARMACEUTICALS, INC
121 SEAPORT BOULEVARD
BOSTON
MA
02210
1
0
0
0
Common Stock, par value $.0001 per share
2021-07-21
4
D
0
20873
0
D
0
D
Option to Purchase Common Stock
155.01
2021-07-21
4
D
0
2343
155.01
D
2016-05-06
2025-05-06
Common Stock, par value $.0001 per share
2343.0
0
D
Option to Purchase Common Stock
167.97
2021-07-21
4
D
0
2706
167.97
D
2015-07-22
2024-07-22
Common Stock, par value $.0001 per share
2706.0
0
D
Option to Purchase Common Stock
138.86
2021-07-21
4
D
0
2294
138.86
D
2017-05-11
2026-05-11
Common Stock, par value $.0001 per share
2294.0
0
D
Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 3,336 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.
/s/ Douglas Barry, Attorney-in-Fact for David R. Brennan.
2021-07-23